Exact Sciences Corp (EXAS)

NasdaqCM • Currently up 45.43 (+76.38%) in today's trading session

2 members of Congress have disclosed 12 trades in Exact Sciences Corp (EXAS) via STOCK Act filings. The most recent disclosure was a sale by Kevin Hern on 24 March 2026. The most active traders have been Kevin Hern (11) and Josh Gottheimer (1). Aggregate disclosed activity totals roughly $115K in purchases and $115K in sales (midpoint estimates from bracketed disclosure amounts).

Exact Sciences Corp is currently trading at $104.91, positioned at 100% of its 52-week range ($38.81 – $104.98).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Copy PortfolioClaim Free Asset
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$104.91
24h Change
+45.43 (+76.38%)
52 Week Range
$38.81—$104.98
View on NASDAQ

Exact Sciences Corp Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for EXAS

Select to highlight on chart
11 transactions
Compliance: 92%
Kevin Hern24 Mar 20263 Apr 2026SaleStock$1,001 - $15,000N/A
Kevin Hern2 Jan 202411 Feb 2024SaleStock$1,001 - $15,000N/A
Kevin Hern31 Jan 202314 Feb 2023SaleStock$1,001 - $15,000N/A
Josh Gottheimer20 Jan 202317 Feb 2023PurchaseStock$1,001 - $15,000N/A
Kevin Hern19 Dec 202213 Jan 2023SaleStock$50,001 - $100,000N/A
Kevin Hern16 May 202214 Jun 2022SaleStock$1,001 - $15,000N/A
Kevin Hern20 May 202115 Jun 2021PurchaseStock$1,001 - $15,000N/A
Kevin Hern20 May 202115 Jun 2021PurchaseStock$1,001 - $15,000N/A
Kevin Hern20 May 202115 Jun 2021PurchaseStock$1,001 - $15,000N/A
Kevin Hern20 May 202115 Jun 2021PurchaseStock$50,001 - $100,000N/A
Kevin Hern27 Jul 202015 Aug 2020PurchaseStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$20.03B

Volume

21.56M

Beta

1.44

P/E Ratio

-95.37

Fundamentals

EPS

$-1.10

Div. Yield

—

Open

$104.91

Day Range

$104.91 — $104.91

Company Information

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Exchange
NASDAQ · USD
Country
US
CEO
Kevin T. Conroy
IPO Date
2001-02-01
Website
www.exactsciences.com

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated...

Earnings

Recent Quarters

Q4 202513 Feb
EPS$-0.45
Miss 316.9%
Q3 20253 Nov
EPS$0.24
Beat 492.0%
Q2 20256 Aug
EPS$0.22
Beat 1200.0%
Q1 20251 May
EPS$-0.21
Beat 43.2%
Q4 202419 Feb
EPS$-0.06
Beat 79.3%
Q3 20245 Nov
EPS$-0.21
Miss 7.2%
Q2 202431 Jul
EPS$-0.09
Beat 75.7%
Q1 20248 May
EPS$-0.50
Miss 5.3%
Q4 202321 Feb
EPS$-0.27
Beat 49.1%
Q3 20231 Nov
EPS$0.00
Beat 100.9%
Q2 20231 Aug
EPS$-0.45
Beat 10.0%
Q1 20239 May
EPS$-0.42
Beat 46.8%
Q4 202221 Feb
EPS$-0.72
Beat 20.0%
Q3 20223 Nov
EPS$-0.84
Beat 23.6%
Q2 20222 Aug
EPS$-0.94
Beat 12.2%
Q1 202226 Apr
EPS$-1.04
Beat 7.1%
Q4 202122 Feb
EPS$-1.28
Miss 40.7%
Q3 20212 Nov
EPS$-0.97
Miss 9.0%
Q2 202128 Jul
EPS$-1.03
Miss 43.1%
Q1 20214 May
EPS$-0.18
Beat 82.7%
Q4 202016 Feb
EPS$-0.09
Beat 52.6%
Q3 202027 Oct
EPS$-0.36
Beat 29.4%
Q2 202030 Jul
EPS$-0.58
Beat 6.5%
Q1 20206 May
EPS$-0.60
Miss 5.3%
Q4 201911 Feb
EPS$-0.37
Beat 0.0%
Q3 201929 Oct
EPS$-0.31
Beat 24.4%
Q2 201929 Jul
EPS$-0.30
Beat 46.4%
Q1 201930 Apr
EPS$-0.66
Miss 3.1%
Q4 201821 Feb
EPS$-0.44
Beat 12.0%
Q3 201830 Oct
EPS$-0.30
Beat 28.6%
Q2 20181 Aug
EPS$-0.30
Beat 9.1%
Q1 201826 Apr
EPS$-0.33
Beat 15.4%
Q4 201722 Feb
EPS$-0.18
Beat 33.3%
Q3 201730 Oct
EPS$-0.23
Beat 23.3%
Q2 201725 Jul
EPS$-0.27
Beat 27.0%
Q1 201727 Apr
EPS$-0.32
Beat 21.9%
Q4 201621 Feb
EPS$-0.34
Beat 12.8%
Q3 201626 Oct
EPS$-0.36
Beat 16.3%
Q2 201626 Jul
EPS$-0.46
Beat 16.4%
Q1 20163 May
EPS$-0.49
Beat 9.3%
Q4 201524 Feb
EPS$-0.41
Beat 14.6%
Q3 201529 Oct
EPS$-0.45
Miss 2.3%
Q2 201520 Jul
EPS$-0.44
Beat 2.2%
Q1 20154 May
EPS$-0.40
Beat 0.0%
Q4 201424 Feb
EPS$-0.38
Beat 2.6%
Q3 201427 Oct
EPS$-0.39
Miss 14.7%
Q2 201422 Jul
EPS$-0.24
Beat 4.0%
Q1 20141 May
EPS$-0.23
Miss 21.1%
Q4 201320 Feb
EPS$-0.17
Beat 10.5%
Q3 201329 Oct
EPS$-0.16
Beat 11.1%
Q2 201323 Jul
EPS$-0.19
Miss 5.6%
Q1 20131 May
EPS$-0.17
Beat 15.0%
Q4 201220 Feb
EPS$-0.22
Miss 29.4%
Q3 201230 Oct
EPS$-0.21
Beat 0.0%
Q2 201225 Jul
EPS$-0.26
Miss 36.8%
Q1 20121 May
EPS$-0.19
Miss 5.6%
Q4 201123 Feb
EPS$-0.18
Miss 5.9%
Q3 20113 Nov
EPS$-0.15
Beat 0.0%
Q2 20112 Aug
EPS$-0.13
Miss 30.0%
Q1 20113 May
EPS$-0.08
Beat 11.1%
Q4 201015 Feb
EPS$-0.08
Beat 0.0%
Q3 201027 Oct
EPS$-0.08
Miss 14.3%
Q2 201028 Jul
EPS$-0.06
Beat 0.0%
Q1 20106 May
EPS$-0.06
Miss 20.0%
Q4 200912 Mar
EPS$-0.05
Q4 200916 Feb
EPS$-0.05
Beat 0.0%
Q2 200913 Aug
EPS$-0.08
Q1 200915 May
EPS$-0.13
Q4 200831 Mar
EPS$-0.08
Q3 20087 Nov
EPS$-0.11
Q2 20088 Aug
EPS$-0.08
Q1 20089 May
EPS$-0.09
Q4 200717 Mar
EPS$-0.15
Q3 20076 Nov
EPS$-0.16
Q2 20078 Aug
EPS$-0.07
Q1 20078 May
EPS$-0.07
Q4 200615 Mar
EPS$-0.09
Q3 20069 Nov
EPS$-0.12
Q2 200624 Jul
EPS$-0.12
Beat 14.3%
Q1 200624 Apr
EPS$-0.14
Miss 7.7%
Q4 200523 Jan
EPS$-0.10
Beat 23.1%
Q3 200524 Oct
EPS$-0.13
Beat 0.0%
Q2 200525 Jul
EPS$-0.15
Beat 0.0%
Q1 200525 Apr
EPS$-0.17
Beat 0.0%
Q4 200424 Jan
EPS$-0.17
Beat 5.6%
Q3 200425 Oct
EPS$-0.17
Beat 10.5%
Q2 200426 Jul
EPS$-0.16
Beat 23.8%
Q1 200426 Apr
EPS$-0.23
Beat 4.2%
Q4 200326 Jan
EPS$-0.29
Miss 422.2%
Q3 200327 Oct
EPS$-0.34
Beat 5.6%
Q2 200321 Jul
EPS$-0.40
Beat 2.4%
Q1 200328 Apr
EPS$-0.40
Miss 2.6%
Q4 200227 Jan
EPS$-0.36
Miss 2.9%
Q3 200221 Oct
EPS$-0.37
Miss 8.8%
Q2 200222 Jul
EPS$-0.40
Miss 2.6%
Q1 200222 Apr
EPS$-0.39
Miss 8.3%
Q4 200130 Jan
EPS$-0.32
Beat 13.5%
Q3 200122 Oct
EPS$-0.27
Beat 10.0%
Q2 200123 Jul
EPS$-0.26
Beat 0.0%
Q1 200114 May
EPS$-0.44
Q1 200125 Apr
EPS$-0.27
Miss 3.9%

2 politicians traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

NVDA

NVIDIA Corporation

20
$215.20+3.70 (+1.75%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

GOOG

Alphabet Inc.

17
$397.05+1.75 (+0.44%)
Communication Services
Held by same politician
1 politician
View Stock

PTSNX

PIMCO Short Term I-3

17
$9.690.00 (0.00%)
Held by same politician
1 politician
View Stock

Frequently Asked Questions about EXAS

Which members of Congress have traded EXAS?
2 members of Congress have disclosed 12 trades in Exact Sciences Corp (EXAS) under the STOCK Act. The most active traders are Kevin Hern and Josh Gottheimer.
When was EXAS most recently disclosed by Congress?
The most recent EXAS disclosure was a sale by Kevin Hern on 24 March 2026.
What is the total disclosed congressional trading volume for EXAS?
Members of Congress have disclosed approximately $115K in EXAS purchases and $115K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in EXAS?
This EXAS page updates as soon as new STOCK Act disclosures are filed for Exact Sciences Corp. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi TrackerJoin our Discord
PoliticiansPortfoliosPricingLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.